What is Turbine?
Turbine operates at the intersection of artificial intelligence and pharmacology, providing a sophisticated virtual lab platform that simulates complex biological experiments. By utilizing high-fidelity computational models and machine learning algorithms, the company enables life science teams to prioritize drug targets, design synergistic combinations, and generate decision-ready hypotheses with unprecedented speed and accuracy. This digital-first approach effectively reduces the reliance on traditional, time-intensive wet-lab processes, positioning Turbine as a transformative force in the drug discovery pipeline. The firm's ability to bridge the gap between raw biological data and actionable clinical insights has made it an essential asset for researchers aiming to streamline the path from discovery to validation.
How much funding has Turbine raised?
Turbine has raised a total of $61.7M across 4 funding rounds:
Other Financing Round
$3.4M
Other Financing Round
$6.8M
Series A
$26.5M
Series B
$25M
Other Financing Round (2019): $3.4M with participation from Esther Dyson, Delin Ventures, Atlantic Labs, Vishal Gulati, and o2h Ventures
Other Financing Round (2021): $6.9M led by Delin Ventures, XTX Ventures, o2h Ventures, Accel, Atlantic Labs, and Boston Millenia Partners
Series A (2023): $26.5M supported by Accel, MassMutual Ventures, Delin Ventures, Mercia Asset Management, and Day One Capital
Series B (2026): $25M featuring Accel, Beiersdorf, Interactive Venture Partners, and Mercia Technologies
Key Investors in Turbine
Accel
Accel is a global venture capital firm that partners with exceptional teams from the inception of their ideas through all phases of private company growth, focusing on supporting innovative companies and entrepreneurs.
Delin Ventures
Delin Ventures is a mission-driven investor and company builder focused on transforming lives through innovations in life sciences and technology, providing operational expertise and long-term partnership.
Mercia Asset Management
Mercia Asset Management provides equity and debt financing to UK businesses with growth ambitions, acting as investment partners from scale-up to exit to accelerate innovation and impact.
What's next for Turbine?
With the successful closure of its latest financing round, Turbine is well-positioned to scale its operations and expand its reach within the global pharmaceutical market. The strategic focus will likely shift toward enhancing the predictive capabilities of its simulation engine and fostering deeper collaborations with major industry players. As the company moves into this next phase of growth, the emphasis will remain on scaling its computational infrastructure to handle increasingly complex biological datasets. By maintaining its commitment to innovation and operational excellence, Turbine is poised to redefine the efficiency standards of modern drug development, ultimately shortening the timeline for bringing life-saving therapies to market.
See full Turbine company page
